Virginia Kaklamani MD
Breast Cancer, Hematologic Oncology
Professor of Medicine at University of Texas Health Science Center San Antonio
Join to view full profile
7979 Wurzbach Rd FL Z5San Antonio, TX 78229
Phone+1 210-450-2872
Fax+1 210-450-0407
Dr. Kaklamani is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
Newton-Wellesley HospitalResidency, Internal Medicine, 1997 - 2000
University of AthensClass of 1996
Certifications & Licensure
TX State Medical License 2014 - 2027
IL State Medical License 2000 - 2017
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014
- CMS Meaningful Use Stage 1 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2011, 2013-2014
- CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2011, 2013-2014
Clinical Trials
- Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
- Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2006 May 04
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Feb 28
Publications & Presentations
PubMed
- Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.Hope S Rugo, Sara M Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi
Clinical Cancer Research. 2026-08-24 - Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United ...Kelly E McCann, Virginia Kaklamani, Noran Osman, Joan Cannon, Lonnie Brent
JCO Oncology Practice. 2026-02-01 - 4 citationsReal-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.Hope S Rugo, Virginia Kaklamani, Heather McArthur, Seth A Wander, William Gradishar
Clinical Cancer Research. 2026-01-06
Lectures
- Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Axillary node metastases with occult primary breast cancerKaklamani V, Gradishar WJ
http://www.uptodate.com/contents/axillary-node-metastases-with-occult-primary-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-08-07
Press Mentions
Adding Tucatinib to First-Line Maintenance Therapy Improves PFS in HER2+ Metastatic Breast CancerDecember 11th, 2025- Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer SymposiumDecember 8th, 2025
- What to Watch for at the 2025 San Antonio Breast Cancer SymposiumDecember 3rd, 2025
Professional Memberships
- Member
Other Languages
- Greek
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
